Clinical review report: Safinamide (Onstryv) (Valeo Pharma Inc.) indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

The objective of this report was to perform a systematic review of the beneficial and harmful effects of safinamide oral tablets, 50 mg or 100 mg, as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease in patients experien...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, May 2020
Edition:	Version: final (with redactions)
Series:	CADTH common drug review
Subjects:	Parkinson Disease / Drug Therapy Monoamine Oxidase Inhibitors / Adverse Effects Drug Therapy, Combination Alanine / Adverse Effects Antiparkinson Agents / Therapeutic Use Monoamine Oxidase Inhibitors / Therapeutic Use Alanine / Therapeutic Use
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK564257
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa